Standard BioTools Terminates Illumina Agreement, Sells Mass Cytometry Business to Multiplex Bio

Illumina Payment Reflects Waiver of Earnout and Royalty Obligations

Standard BioTools disclosed that on July 24, 2026, it entered into a Termination, Waiver and Release Agreement with Illumina. Under this agreement, the company received approximately $30 million in cash from Illumina. In exchange, Standard BioTools agreed to waive its rights to earnout payments based on fiscal year 2026 net revenues from SomaScan assay services and other SOMAmer-based assay services, as well as sales of SOMAmer-based array kits and SOMAmer-based next-generation sequencing library preparation kits. The earnout obligation had been established under the Stock Purchase Agreement between the two companies dated June 22, 2025.

The company also agreed to terminate three separate agreements that had been entered into on January 30, 2026, in connection with the closing of the Illumina Stock Purchase Agreement. These termination agreements included a royalty agreement for net revenues from SOMAmer-based next-generation sequencing library preparation kit sales, a license agreement providing Illumina-specified intellectual property rights for Single SOMAmer development, and a royalty agreement for Single SOMAmers. The filing states that the Termination Agreement represents a complete settlement of these future payment obligations in exchange for the lump sum cash payment.

Mass Cytometry Business Sale to Multiplex Bio

On July 28, 2026, Standard BioTools entered into a Share and Asset Purchase Agreement with Multiplex Bio Inc., pursuant to which Multiplex Bio will acquire the company's mass cytometry business. The disclosure indicates that the aggregate purchase price for the transaction is $5 million on a cash-free and debt-free basis, subject to customary adjustments. However, the company will not receive cash consideration at the time of closing. Instead, the entire Closing Payment will be payable through the issuance by Multiplex Bio of a promissory note bearing interest at 6% per annum and maturing on the fifth anniversary of the Closing.

In addition to the base purchase price, the Purchase Agreement provides for potential additional consideration. Standard BioTools may receive an additional $5 million if Multiplex Bio consummates a qualifying sale transaction for consideration exceeding a specified dollar threshold within ten years of the Closing. The filing does not disclose the specific dollar threshold required to trigger this contingent payment obligation. The company also indicated that it will provide specified transition services to Multiplex Bio following the Closing through a transition services agreement to be entered into by the parties.

Financing Requirements and Working Capital Obligations

The Purchase Agreement contains provisions addressing financing arrangements necessary for Multiplex Bio to operate the acquired business. Multiplex Bio is required to use reasonable best efforts to obtain a senior secured working capital loan facility on terms reasonably satisfactory to the company. If Multiplex Bio is unable to obtain such financing prior to Closing despite making such efforts, the disclosure states that Standard BioTools must provide Multiplex Bio with a working capital loan at Closing in an amount of up to $10 million.

This financing contingency represents a potential additional capital commitment by Standard BioTools in the event that external financing arrangements prove unavailable to the buyer. The filing does not specify whether Standard BioTools expects to provide this working capital loan or whether it anticipates that Multiplex Bio will secure the required senior secured facility independently. The structure ensures that the mass cytometry business can continue operating following the transfer to the new owner.

Closing Conditions and Stockholder Approval Requirements

The consummation of the transaction with Multiplex Bio is subject to customary closing conditions, as well as two additional significant conditions that introduce material uncertainty regarding timing. First, the disclosure states that receipt of approval of the company's stockholders for the transaction is a required closing condition. Second, the consummation of Standard BioTools' pending merger with Treeline Biosciences Inc. is also specified as a closing condition. These dual contingencies mean that both the Multiplex Bio transaction and the Treeline merger must be successfully completed for the mass cytometry business sale to close.

The filing indicates that the parties contemplate entering into certain ancillary agreements at the time of Closing, including the transition services agreement mentioned previously. The presence of these contingencies, particularly the Treeline merger requirement, introduces timing complexity into the transaction structure. Investors should note that delays or complications with either the stockholder vote or the Treeline merger could affect the timing or completion of the mass cytometry business sale.

Termination Rights and Deal Protection Mechanisms

The Purchase Agreement provides customary termination rights for both Standard BioTools and Multiplex Bio. Each party has the ability to terminate the agreement if the transaction has not been consummated on or before June 30, 2027, subject to up to two automatic three-month extensions under specified circumstances. This structure provides a defined endpoint for closing obligations while preserving flexibility for circumstances that may warrant additional time to satisfy closing conditions.

The Purchase Agreement also includes deal protection mechanisms. Standard BioTools is subject to a customary non-solicitation restriction on its ability to solicit or facilitate alternative proposals to acquire the mass cytometry business. However, the agreement provides a customary fiduciary out that permits the company's board of directors, prior to stockholder approval, to change its recommendation or terminate the Purchase Agreement to accept an unsolicited competing proposal that is more favorable to stockholders from a financial perspective, subject to Multiplex Bio's notice and matching rights. This provision preserves board flexibility while protecting the buyer's interests through matching rights.

Termination Fees and Reimbursement Obligations

The Purchase Agreement contains specified financial consequences if the transaction terminates under certain circumstances. The filing discloses that upon termination under specified circumstances, Standard BioTools will be required to make a payment to Multiplex Bio equal to $1 million in cash, referred to as the Termination Fee. Additionally, the company will be required to reimburse Multiplex Bio's reasonable out-of-pocket fees in connection with the transaction in specified amounts if closing does not occur by certain dates.

Specifically, the company must reimburse up to $125,000 if the transaction is not consummated prior to December 31, 2026, and up to an additional $125,000 if the transaction is not consummated prior to March 31, 2027. Importantly, the filing states that the amount of any such reimbursement will be credited against any payment of the Termination Fee. This structure means that the company's maximum cash outflow from termination fees and expense reimbursements is capped at $1 million, with reimbursements serving to reduce rather than supplement the termination fee obligation.

Strategic Implications of Illumina Payment and Business Disposition

The combination of the Illumina payment and the mass cytometry business sale represents a significant restructuring of Standard BioTools' business model and financial position. The $30 million Illumina payment eliminates future contingent obligations while providing immediate liquidity, allowing the company to reduce its commitment to SOMAmer-based product lines that Illumina now controls. This settlement may reflect Illumina's desire to eliminate potential disputes regarding earnout calculations or royalty payments following its initial investment in Standard BioTools' SomaScan technology.

The disposition of the mass cytometry business, meanwhile, appears designed to streamline the company's operations. The filing does not provide details regarding the mass cytometry business's historical revenue, profitability, or strategic importance to the company. However, the decision to divest this business while simultaneously settling the Illumina relationship suggests that management has determined this business is not core to the company's future strategy, particularly given the pending Treeline merger. The $5 million base purchase price combined with potential future payments of up to $5 million suggests moderate valuation but acknowledges potential upside in the business if Multiplex Bio achieves a successful exit.

Impact on Balance Sheet and Future Obligations

The disclosure indicates that the $30 million received from Illumina will meaningfully improve Standard BioTools' cash position. This payment eliminates contingent liabilities related to 2026 earnout calculations and future royalty streams, removing uncertainty regarding future cash outflows. The filing states that these payments and terminations were recorded as of July 24, 2026, suggesting that the financial benefits are now crystallized in the company's accounting records.

Conversely, the mass cytometry business sale creates potential future obligations and contingencies. While the company will not receive immediate cash at closing, it will receive a $5 million promissory note bearing 6% interest over five years. The potential $10 million working capital loan obligation to Multiplex Bio, if financing is not obtained externally, represents a contingent liability. These obligations, combined with the potential $5 million additional consideration contingent on Multiplex Bio achieving a qualifying transaction within ten years, create a mixed financial picture. Investors should monitor how the company accounts for these arrangements in future quarterly and annual filings.

Treeline Merger Contingency and Transaction Timeline

The filing's reference to the company's pending merger with Treeline Biosciences as a closing condition for the Multiplex Bio transaction introduces an important interdependency between these two separate transactions. While the current filing provides no details regarding the Treeline merger, the contingency provision indicates that Standard BioTools is simultaneously managing this merger while executing the mass cytometry business sale. The June 30, 2027 termination date for the Multiplex Bio Purchase Agreement provides approximately one year from the July 28, 2026 signing date for both the Treeline merger and the mass cytometry sale to be completed.

This timeline raises questions about execution sequencing and operational integration. The disclosure does not clarify whether the Treeline merger is expected to close before, after, or simultaneously with the Multiplex Bio transaction. The presence of the Treeline merger as a closing condition suggests that the company's board determined these transactions are related and that the mass cytometry business sale should only close if the Treeline merger is successfully consummated. Investors should expect additional disclosures regarding the Treeline merger in future regulatory filings, which will provide clarity on the overall strategic restructuring being undertaken by the company.

Forward-Looking Uncertainty and Regulatory Considerations

The filing notes that the disclosure contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the disposition of the mass cytometry business and the expected timing of such disposition. The presence of this forward-looking statement disclaimer indicates that the company recognizes the inherent uncertainties in these transactions. Multiple closing conditions, particularly stockholder approval and the Treeline merger requirement, introduce material uncertainties regarding whether and when these transactions will be completed.

The filing also indicates that written communications under Rule 425 of the Securities Act are contemplated, suggesting that additional communications regarding the transactions may be issued to shareholders in connection with the anticipated stockholder vote. Investors should anticipate additional disclosures as the company moves toward stockholder meetings and closing preparation. The regulatory framework governing these transactions, including potential Hart-Scott-Rodino considerations or other regulatory approvals, is not addressed in the current filing, suggesting these may not be material barriers or that they have been considered separately by the parties.